Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

NANJING, China, Sept. 14, 2024 /PRNewswire/ -- On September 2, 2024, Simcere Pharmaceuticals Group Ltd. (2096.HK) announced that Sanbexin Sublingual Tablets (Edaravone and Dexborneol sublingual tablets), an innovative drug for stroke, has been granted the Breakthrough Therapy designation by the U.S. Food and Drug Administration (FDA) for the treatment of Acute Ischemic Stroke (AIS). Sanbexin sublingual tablets is the first innovative drug in the world to be designated with the Breakthrough Therapy by the FDA for the treatment of stroke.

The Breakthrough Therapy designation stems from the provisions of 《Food and Drug Administration Safety and Innovation Act》. It is designed to expedite the development and regulatory review of drugs for treating serious diseases and addressing significant unmet medical needs. The designation will be beneficial for the drugs to obtain the FDA's guidance in the clinical development, accelerate the overseas clinical development process, and is also expected to significantly shorten the time for marketing review through the priority review designation.

The Breakthrough Therapy designation is based on the significant improvement in efficacy metrics demonstrated by the sublingual tablets in a previous clinical study. The data from a multicenter, randomized, double-blind, parallel, placebo-controlled Phase III clinical study in China for the treatment of AIS demonstrated that Sanbexin sublingual tablets significantly improved neurological recovery and independent living ability in patients with AIS compared to placebo, meeting the expected efficacy endpoints with a favorable safety profile. JAMA Neurology published the study's key findings online.

The designation will be beneficial for Simcere to obtain the FDA's guidance in the clinical development of Sanbexin sublingual tablets, accelerate the overseas clinical development process, and is also expected to significantly shorten the time for marketing review through the priority review designation.

According to a recent article in The Lancet, stroke is the second leading cause of death and disability worldwide, with 12 million new cases and 6.6 million deaths each year. Among them, acute ischemic stroke is the most common type of stroke, accounting for about 70% of all strokes, and constituting a heavy disease burden for all countries around the world. The efficacy of acute ischemic stroke treatment is highly time-dependent. Receiving treatment as early as possible will help patients to improve their disease outcome and avoid disability.

Sanbexin sublingual tablets is a brain cytoprotective agent composed of edaravone and dexborneol, two active ingredients with synergistic anti-oxidant and anti-inflammatory effects, which can significantly reduce brain cell injury or impairment caused by AIS. Such unique sublingual formulation can quickly disintegrate once in contact with the saliva once place under the tongue and can be absorbed into the blood through the sublingual venous plexus, which is expected to increase the flexibility of stroke treatment. Sequential therapy consisting of the marketed Sanbexin concentrated solution for Injection. These two formulae enable patients to receive a complete course of treatment in and outside of the hospital.

On June 28, 2023, the new drug application (NDA) for Sanbexin sublingual tablets in China is accepted by the National Medical Products Administration. The first indication is for the improvement of neurological symptoms, daily activities, and functional impairment due to AIS. Phase I clinical trials for Sanbexin sublingual tablets on healthy volunteers have been completed in the United States.

CONTACT: Haoyun Huang, huanghaoyun@simcere.com 

** The press release content is from PR Newswire. Bastille Post is not involved in its creation. **

Breakthrough Therapy designation for Sanbexin sublingual tablets granted by the United States Food and Drug Administration

OpenAI/Astra, Perplexity, DeepSeek, Google Gemini and xAI/Grok are confronted with the same work: a meta-reading experiment turns literary criticism into a comparative laboratory for artificial intelligence.

PARIS, Sept. 19, 2026 /PRNewswire/ -- What if, in order to understand artificial intelligences, we gave them exactly the same book to read?

That is the experiment now accompanying "Dialogue Between a Thinker and AI".

After hundreds of hours of dialogue, human thought, archives, questions, and contradictions gave rise to a book whose pen was entrusted to artificial intelligence.

https://www.dialoguebetweenathinkerandai.com/en/

Today, the book also exists materially: its French and English editions are in print. But the experiment does not end with the book. It now turns back toward the artificial intelligences themselves.

We didn't ask AI to judge the book. We asked AIs to read it — and then to read each other.

The complete corpus is submitted to several major systems:

OpenAI / Astra, Perplexity, DeepSeek, Google Gemini, and xAI / Grok.

They all receive the same object. But do they produce the same reading?

https://www.dialoguebetweenathinkerandai.com/en/meta-reading/

The objective is not to organize a competition between models.

It is precisely the opposite.

The purpose is to observe their convergences, divergences, and blind spots.

Which concepts do they spontaneously identify? Which theses do they consider central? Which passages do they connect? Where do their interpretations diverge?

And above all: what happens when each is subsequently given access to the analyses produced by the others? At that moment, a meta-reading emerges.

AI no longer merely reads the book.

It reads another AI reading the book.

A third system can then analyze that confrontation. Commentary becomes corpus. The corpus becomes new material for analysis.

For centuries, we have used critics to better understand books.

This experiment also proposes the reverse movement:

using a book to better understand those who read it.

The same work thus becomes a kind of cognitive mirror placed before several artificial-intelligence architectures. This mirror does not ask: "Which AI is right?"

What Gemini thought of the analysis produced by Grok.

DeepSeek's response to the critique by OpenAI Astra.

It asks: "Why don't they see exactly the same thing?"

The distinction is essential. Because their divergences themselves become information.

This experiment does not delegate human judgment.

It demands more of it. The human remains the one who compares, doubts, contextualizes, and decides.

The machine produces readings. The human also observes the gaps between those readings.

Dialogue Between a Thinker and AI thus becomes simultaneously a book, a corpus, and an open experiment into the plurality of artificial intelligences.

The book was meant to be read by humans.

It now also becomes an object through which humans can watch AIs read.

NOTES TO EDITORS

The meta-reading experiment makes it possible to examine, among other things:

• what Google Gemini observes in the analysis produced by xAI/Grok;
• DeepSeek's response to the critique produced by OpenAI/Astra;
• the convergences, divergences and blind spots revealed by confronting the different readings.

"We didn't ask AI to judge the book. We asked AIs to read it — and then to read one another."

https://www.dialoguebetweenathinkerandai.com/en/meta-reading/
https://www.dialoguebetweenathinkerandai.com/en/

Media Contact : Thierry Ehrmann, ir@artmarket.com 

** This press release is distributed by PR Newswire through automated distribution system, for which the client assumes full responsibility. **

ARTPRICE NEWS: A WORLD-BOOK BECOMES A MIRROR FOR ARTIFICIAL INTELLIGENCE